Wall Street brokerages expect that OptiNose Inc (NASDAQ:OPTN) will report sales of $2.56 million for the current quarter, Zacks reports. Two analysts have made estimates for OptiNose’s earnings, with the highest sales estimate coming in at $2.60 million and the lowest estimate coming in at $2.52 million. The company is expected to report its next earnings results on Tuesday, March 12th.

On average, analysts expect that OptiNose will report full year sales of $6.35 million for the current year, with estimates ranging from $6.10 million to $6.60 million. For the next financial year, analysts forecast that the company will report sales of $37.92 million, with estimates ranging from $37.73 million to $38.10 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for OptiNose.

OptiNose (NASDAQ:OPTN) last announced its earnings results on Tuesday, November 13th. The company reported ($0.61) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.11. The company had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.57 million.

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of OptiNose in a research note on Tuesday, August 7th. They issued an “overweight” rating and a $30.00 target price for the company. Zacks Investment Research lowered shares of OptiNose from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. BMO Capital Markets reduced their target price on shares of OptiNose from $30.00 to $28.00 and set an “outperform” rating for the company in a research note on Wednesday, August 15th. Finally, Piper Jaffray Companies set a $30.00 target price on shares of OptiNose and gave the stock a “buy” rating in a research note on Tuesday, August 14th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. OptiNose currently has a consensus rating of “Buy” and a consensus target price of $28.75.

Institutional investors have recently bought and sold shares of the company. American Century Companies Inc. boosted its stake in shares of OptiNose by 46.5% during the 2nd quarter. American Century Companies Inc. now owns 157,790 shares of the company’s stock worth $4,415,000 after buying an additional 50,058 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of OptiNose by 60.0% during the 2nd quarter. Wells Fargo & Company MN now owns 454,160 shares of the company’s stock worth $12,708,000 after buying an additional 170,382 shares during the last quarter. Swiss National Bank acquired a new position in shares of OptiNose during the 2nd quarter worth about $554,000. BlackRock Inc. boosted its stake in shares of OptiNose by 336.0% during the 2nd quarter. BlackRock Inc. now owns 997,257 shares of the company’s stock worth $27,903,000 after buying an additional 768,521 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of OptiNose by 1,054.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 178,289 shares of the company’s stock worth $4,987,000 after buying an additional 162,851 shares during the last quarter. Institutional investors own 47.81% of the company’s stock.

NASDAQ OPTN traded down $0.41 on Wednesday, reaching $9.91. The company had a trading volume of 151,700 shares, compared to its average volume of 206,433. The firm has a market cap of $425.47 million and a PE ratio of -1.76. The company has a current ratio of 10.44, a quick ratio of 10.13 and a debt-to-equity ratio of 0.51. OptiNose has a 1-year low of $9.78 and a 1-year high of $30.00.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Featured Article: Book Value Of Equity Per Share – BVPS Explained

Get a free copy of the Zacks research report on OptiNose (OPTN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OptiNose (NASDAQ:OPTN)

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.